Drug information of Adenovirus types 4 and 7 live, oral
Adenovirus types 4 and 7 live, oral
Live virus vaccine. Available in US as adenovirus type 4 and type 7 vaccine live oral containing viable, selected strains of human adenovirus type 4 and type 7 prepared in human diploid fibroblast cell cultures. Used to stimulate active immunity to the adenovirus serotypes represented in the vaccine.
Mechanism of effect
Live oral vaccine that replicates in intestinal tract and induces immunity in persons with low or no pre-existing neutralizing antibodies to adenoviruses types 4 and 7
Duration: Viral shedding not detected after 28 days
Onset: Viral shedding in the stool starts at 7 days; seroconversion starts at 26 days following vaccination
Absorption: Not detected in serum (limited data)
Adenovirus Active Immunization
Indicated for active immunization of military populations for prevention of febrile acute respiratory disease caused by adenovirus types 4 and 7
Aged 17-50 years: Single vaccine dose consists of 2 tablets: 1 tablet of adenovirus type 4 and one tablet of adenovirus type 7
Swallow tablets whole, do not chew, crush, or split; chewing a tablet could expose the upper respiratory tract to live adenovirus leading to disease
<17 years: Safety and efficacy not established
InteractionsPrednisolone , Cabazitaxel , Alefacept , Abatacept , Azathioprine , Epirubicin , Oxaliplatin , Irinotecan , Ifosfamide , Betamethasone , Carmustine , Temsirolimus , Daclizumab , Risankizumab , Tildrakizumab , vedolizumab , Muromonab-CD3 , Guselkumab , Ustekinumab , Nelarabine , Azacitidine , Alemtuzumab , Dupilumab , Ocrelizumab , Ofatumumab , Pralatrexate , Anakinra , Ibrutinib , Baricitinib , Pentostatin , Floxuridine , thiotepa , Idarubicin , Tocilizumab , Ibritumomab tiuxetan , Tisagenlecleucel , Axicabtagene ciloleucel , cortisone , Certolizumab , Altretamine , Sarilumab , Teniposide , Etoposide , Carboplatin , cladribine , Chlorambucil , Fluorouracil , mercaptopurine , prednisone , Hydroxy urea , Hydrocortisone , Vinblastin , Vincristin , Vinorelbine , Capecitabine , Lomustine , Mycophenolate mofetil , Methotrexate , Methylprednisolone , Melphalan , Mitoxantrone , Cytarabine , Sirolimus , Cisplatin , Cyclophosphamide , Fludarabine phosphate , Fingolimod , Dactinomycin , Deflazacort , Dexamethasone , Docetaxel , Doxorubicin , Rituximab , Temozolomide , Topotecan , Thioguanine , Gemcitabine , Daunorubicin , Dacarbazine , Bleomycin , Busulfan , Procarbazine , Paclitaxel , Tacrolimus , Triamcinolone , secukinumab , Anthrax immune globulin
Vomiting or diarrhea could decrease effectiveness of vaccine
Safety has not been evaluated in individuals with altered immunocompetence
Contains live viruses that are shed in the stool and can cause disease if transmitted; those vaccinated should avoid close contact with children younger than 7 years and immunocompromised individuals
Tablets contain human albumin (<0.3 mg/tablet), which could theortetically increase risk transmission of blood borne diseases (e.g., Creuzfeldt-Jakob disease)
Effective immunity may not occur in all vaccinated patients
Points of recommendation
- swallow the vaccine tablets whole with a small amount of water and without chewing or crushing them.
- inform clinician if you accidentally chew a vaccine tablet.
- adenovirus type 4 and type 7 vaccine is a live virus vaccine and that vaccine virus is shed in the stool for up to 28 days following vaccination and can be transmitted to and cause disease in close contacts during this period. To minimize risk of transmission of vaccine virus, advise patients to take precautions (i.e., frequent hand washing, especially after bowel movements) for 28 days after vaccination if in close contact with children younger than 7 years, immunocompromised individuals, or pregnant women.
- Importance of women informing clinician if they are or plan to become pregnant or are breast-feeding. Advise women to avoid pregnancy for at least 6 weeks following vaccination.